New antiplatelet drugs

Bibliography

• FITZGERALD DJ, ROY L, CATELLA F, FITZGERALD GA: Platelet activation in unstable coronary disease. New Engl. 1 Med. (1986) 315:983–989.
   PubMed Web of Science ®Google Scholar
• FUSTER V, STEELE PM, CHESEBRO JH: Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. 1 Am. Coll. Cardiol. (1985) 5:175B–184B.
   Google Scholar
• ANTIPLATELET TRIALISTS' COLLABORATION: Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br. Med. 1 (1988) 296:320–331.
   Google Scholar
• A key study demonstrating the benefit of antiplatelet therapy in myocardial infarction, stroke and cardiovascular mortality.
   Google Scholar
• ASHBY B, DANIEL JL, SMITH JB: Mechanisms of platelet activation and inhibition. Platelets in Health & Disease (1990) 4(1):1–26.
   Web of Science ®Google Scholar
• STEERING COMMITTEE OF THE PHYSICIANS' HEALTH STUDY RESEARCH GROUP: Final report on the aspirin component of the ongoing physicians' health study. New Engl. 1 Med. (1989) 321:129–135.
   Google Scholar
• The pivotal study showing the benefit of aspirin in primary prevention of myocardial infarction.
   Google Scholar
• ROTH GJ, MAJERUS PW: The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. 1 Clin. Invest. (1975) 56:260–264.
   Google Scholar
• FITZGERALD GA: Modern drug therapy: dipyridamole. New Engl. 1 Med. (1987) 316:1247–1257.
   PubMed Web of Science ®Google Scholar
• SCHROR K: The basic pharmacology of ticlopidine and clopidogrel. Platelets (1993) 4:252–261.
   PubMed Web of Science ®Google Scholar
• SALTIEL E, WARD A: Tidopidine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in platelet-dependent disease states. Drugs (1987) 34:222–262.
   PubMed Web of Science ®Google Scholar
• EPIC INVESTIGATORS: Use of a monoclonal antibody directed against the platelet glycoprotein llb/Illa receptor in high-risk coronary angioplasty. New Engl. I Med. (1994) 330: 956–961.
   PubMed Web of Science ®Google Scholar
• The first clinical result demonstrating GPIIb/IIIa blockade.
   Google Scholar
• FIDDLER GI, LUMLEY P: Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers: a review. Circulation (1990) 21:1269–1279.
   Google Scholar
• HARKER LA: New antithrombotic strategies for resistant thrombotic processes. I Clin. Pharma-col. (1994) 34(1):3–16.
   PubMed Web of Science ®Google Scholar
• WEISS HJ, TURITTO VT, BAUMGARTNER HR: Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. Shear-dependent decrease of adhesion in von Willebrand's disease and the Bernard-Soulier syndrome. I Lab. Clin. Med. (1978) 92:750–764.
   Google Scholar
• CHOW TW, HELLUMUS JD, MOAKE JL, KROLL MH: Shear stress-induced von Willebrand factor binding to platelet glycoprotein IB initiates calcium influx associated with aggregation. Blood (1992) 80:113–120.
   PubMed Web of Science ®Google Scholar
• PHILIPS DR, CHARO IF, SCARBOROUGH RM: GPIIb/IIIa: the responsive integrin. Cell (1991) 65:359–362.
   PubMed Web of Science ®Google Scholar
• A key review of the biology of GPIIb/IIIa.
   Google Scholar
• WEISEL JVV, NAGASWAMI C, VILA1RE G, BENNETT JS: Examination of the platelet membrane glycoprotein Ilb-IIIa complex and its interaction with fibrinogen and other ligands by electron microscopy. J. Biol. Chem. (1992) 267:16637.
   PubMed Web of Science ®Google Scholar
• HANSON SR, HARKER LA: Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethylketone. Proc. Natl. Acad. Sci. USA (1988) 85:3184–3188.
   PubMed Web of Science ®Google Scholar
• KRISHNASWAMY S, FIELD KA, EDGINTON TS, MORRISSEY JH, MANN KG: Role of the membrane surface in the activation of human coagulation factor X. I Biol. Chem. (1992) 267:26110–26120.
   Web of Science ®Google Scholar
• DUPONT MERCK PHARMACEUTICAL COMPANY: Novel antiplatelet therapies: recent ad-vances in the development of platelet GPM/Ilia receptor antagonists. DuPont Merck Company Brochure (1996).
   Google Scholar
• CHARO IF, SCARBOROUGH RM, DUMEE CP, et al.: Pharmacodynamics of the GPI1b-Illa antagonist Integrelin: Phase I clinical studies in normal healthy volunteers. Circulation (1992) 86(Suppl. I):1-260, Abstract.
   Google Scholar
• SCHULMAN SP, GOLDSCHMIDT-CLERMONT PJ, et al.: Integrelin in unstable angina: a dou-ble-blind randomized trial. Circulation (1993) 88:1-608, Abstract.
   Google Scholar
• Cost-effectiveness of ReoPro. Scrip (1994) 1981:24.
   Google Scholar
• Merck Aggrastat prime studies in 4900 patients will conclude in 1997. FDC Reports, The Pink Sheet (1996) 58:14 T&G 8-T&G9.
   Google Scholar
• NAR H, WEISENBERGER H, MULLER TH, DEISCHEL G, KRAUSE J: Tolerability and platelet fibrinogen receptor occupancy (FRO) after oral treatment with BIBU 104 XX in healthy volunteers. I Thromb. Haemost. (1995) 73:6, Abstract 1592.
   Google Scholar
• FOSTER MR, PIKE NB, HORNBY EJ, et al.: GR144053, a potent and specific non-peptide fibrinogen receptor antagonist on human platelets in vitro. Thromb. Haemost. (1993) 69(6). Abstract 64.
   Google Scholar
• PIKE NB, FOSTER MR, HORNBY EJ, LUMLEY P: Effect of the fibrinogen receptor antagonist GR144053 upon platelet aggregation ex vivo following intravenous and oral administration to the marmoset and cynomolgus monkey. Thromb. Haemost. (1993) 69(6). Abstract 1886.
   Google Scholar
• COOK NS, BRUTTGER 0, PALLY C, HAGENBACH A: The effects of two synthetic glycoprotein Hb/Illa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active. Thromb. Haemost. (1993) 70(5):838–847.
   PubMed Web of Science ®Google Scholar
• ZABLOCKI JA, MIYANO M, GARLAND RB, et al.: Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GPI1b/Illa receptor. J. Med. Chem. (1993) 36:13 1811–1819.
   PubMed Web of Science ®Google Scholar
• Searle gears up to move new chemical entities (NCE) into Phase HI. Scrip (1996) 2169:9.
   Google Scholar
• SAMANEN J, ALI F, BARTON L, et al.: GPI:lb/Ina antagonists with long oral duration. 209th ACS. Anaheim (1995). Abstract 237.
   Google Scholar
• GOODFELLOW V: Cambridge Healthtech Institute's Fourth Annual Conference on the Development of Small Molecule Mimetic Drugs. Washington, D.C. (2–3 May, 1996) IDdb Meeting Report (Session on antagonists).
   Google Scholar
• Boehringer Ingelheim: "Innovative R&D key to success." Scrip (1995) 2028:8.
   Google Scholar
• Sanofi Information Meeting. Sanofi Company Brochure (1995).
   Google Scholar
• Ono Pharmaceutical Co. Ltd: Annual Report (1995). 2-1-5 Doshomachi, Chuo-ku, Osaka 541, Japan.
   Google Scholar
• Biogen announces Phase Ill trial results with Hirulog. Biogen, Inc.: Press Release (31 October 1994).
   Google Scholar
• Company pipeline. Biogen, Inc.: Company Communication. (4 April 1996).
   Google Scholar
• MACDONALD CHASTAIN M, SHUMAN RT, SMITH G, HAHN RA (Sponsor: FRANKLIN R): Salvage of reperfused ischemic myocardium by LY293435 (LY), a thrombin inhibitor, in a non-thrombotic canine model. FASEB 1 (1995) 9:3, Abstract 3611.
   Google Scholar
• New drugs for angioplasty/restenosis. Scrip (1995) 2015:30.
   Google Scholar
• Bleak future for hirudin. Scrip (1996) 2115:23.
   Google Scholar
• MOLHOEK GP, LAARMAN GJ, LOK DJA, et al.: Effects of recombinant hirudin (HBW 023) on early and late coronary patency in acute myocardial infarction patients treated with streptoki-nase (the HIT-SK study). Eur. Heart J. (1995) 16(Suppl.). Abstract 1013.
   Google Scholar
• Pipeline: antibacterials; asthma; cardiovascular disorders; transplant rejection; psycho-therapeutics. Pharm. Marketing (1995) 7:6–52.
   Google Scholar
• Cancellations/suspensions. Clin. Trials Monitor (1996) 56:3–4.
   Google Scholar
• WITYAK J, SIELECKI T: Glycoprotein Hb/HIa antagonists. Exp. Opin. Ther. Patents (1996) 6(11):1175–1194.
   Web of Science ®Google Scholar